Novo Nordisk hit with FDA warning letter

The Food and Drug Administration has formally warned Novo Nordisk, the company behind Ozempic and Wegovy, that it broke federal rules for reporting possible side effects after those drugs were already on the market. The letter, dated March 5, 2026, followed an FDA inspection at Novo Nordisk’s Plainsboro, New Jersey, site from January 13 to February 7, 2025. The agency said the inspection found “serious violations” of postmarketing adverse drug experience reporting requirements under federal law and drug regulations. (fda.gov) That phrase sounds bureaucratic, but the underlying issue is simple. Once a drug is selling, the manufacturer has to collect, evaluate, and quickly send certain safety reports to the FDA so the agency can spot patterns that did not show up in clinical trials. The FDA’s MedWatch system depends on that flow of information, and the company’s legal duty is not optional. The agency says warning letters are reserved for significant violations and are meant to force correction, not just to document a problem. (fda.gov 1) (fda.gov 2) What the FDA says Novo failed to do is more specific, and more damaging, than a generic paperwork lapse. In the warning letter, the agency says Novo did not maintain adequate written procedures for handling adverse-event reports and did not comply with the rules that govern how those reports must be investigated and submitted. Trade and news reports based on the letter and inspection records say the missed or mishandled cases involved semaglutide drugs and included reports of two deaths and one completed suicide that were not properly escalated as required. The FDA did not say those events were proven to be caused by the drugs. It said Novo failed to handle the signals the way the law requires. (fda.gov) (bloomberg.com) (biospace.com) That distinction matters because the GLP-1 market is now so large that postmarket surveillance is part of the product itself. Ozempic and Wegovy are not niche medicines. They are among the most visible and commercially important drugs in the world, used in diabetes and obesity care by huge numbers of patients. When a company that central to the boom is accused of “systemic failures” in safety reporting, the story is not just about Novo Nordisk. It is about whether the monitoring system around blockbuster medicines can keep up with the scale of their use. (usatoday.com) (raps.org) Novo Nordisk’s public response has been careful and narrow. The company said on March 10 that it had received the warning letter, that it had already been working on corrective and preventive actions since getting an FDA Form 483 on February 7, 2025, and that the agency acknowledged “significant measures” it had taken over the past year. Novo also said the letter “does not make any conclusions about the quality or safety of our medicines” and that it does not expect any impact on production or on the financial guidance it gave in February. (novonordisk.mediaroom.com) The timeline tells its own story. FDA inspectors raised concerns in early 2025. Novo says it responded within the deadline and then sent seven updates. Even so, the agency still escalated the matter to a warning letter a full year later. That usually means the FDA concluded the fixes were incomplete, inadequately documented, or not persuasive enough to close the case. The letter was addressed to David S. Moore, president of Novo Nordisk Inc., at 800 Scudders Mill Road in Plainsboro. (fda.gov) (novonordisk.mediaroom.com)